Free tool
FAERS Monitor: Alunbrig
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208772 or its brand name (Alunbrig, Brigatinib). Reports on generic versions are filed under their own applications.
Reports
3,655
Serious
3,259
89% of reports
Hospitalization
1,004
Death reported
788
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death431
- non-small cell lung cancer396
- off label use307
- diarrhoea255
- metastases to central nervous system242
- nausea234
- lung neoplasm malignant225
- blood creatine phosphokinase increased220
- fatigue216
- product dose omission issue204
- drug ineffective185
- neoplasm progression180
- dyspnoea131
- vomiting130
- rash124
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 57 |
| 2018 | 244 |
| 2019 | 310 |
| 2020 | 374 |
| 2021 | 526 |
| 2022 | 579 |
| 2023 | 486 |
| 2024 | 541 |
| 2025 | 377 |
| 2026 | 160 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,504 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| non-small cell lung cancerSignal | 396 | 518.5 | 470.3 | 187,197 |
| metastases to central nervous systemSignal | 242 | 110.0 | 97.3 | 25,560 |
| blood creatine phosphokinase increasedSignal | 220 | 44.3 | 39.0 | 9,213 |
| lung neoplasm malignantSignal | 225 | 31.7 | 27.9 | 6,629 |
| neoplasm progressionSignal | 180 | 29.9 | 26.0 | 4,990 |
| product dose omission issueSignal | 204 | 4.0 | 3.5 | 461 |
| deathSignal | 431 | 2.9 | 2.6 | 549 |
| diarrhoeaSignal | 255 | 2.3 | 2.0 | 186 |
| off label useSignal | 307 | 2.0 | 1.8 | 163 |
| nausea | 234 | 1.7 | 1.5 | 70 |
| rash | 124 | 1.6 | 1.4 | 31 |
| fatigue | 216 | 1.6 | 1.4 | 49 |
| vomiting | 130 | 1.6 | 1.3 | 29 |
| dyspnoea | 131 | 1.3 | 1.1 | 11 |
| drug ineffective | 185 | 0.8 | 0.7 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.